MedTrace Logo

SNC116 Therapy for Refractory Systemic Lupus Erythematosus

NCT07748156 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-08-05

No results posted yet for this study

Summary

This study aims to evaluate the safety and tolerability of SNC116 in treating patients with systemic lupus erythematosus.

Conditions

Interventions

DRUG

SNC116

The formulation of SNC116 is an injection solution. The initial dose is 2E8 TU and it is administered via a single intravenous infusion.

Sponsors & Collaborators

  • Shanghai Simnova Biotechnology Co.,Ltd.

    collaborator INDUSTRY

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    lead OTHER

Principal Investigators

  • Lingyun Sun, Doctor · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2030-01-31
Completion
2030-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07748156 on ClinicalTrials.gov